Physician profile
Gerald J Harder
NPI 1457375396
$1,250.27
in general payments reported to CMS, 2019-2025
22 companies · $90.87 in 2025
The $90.87 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $46.92 · 2021: $357 · 2022: $184 · 2023: $288 · 2024: $126 · 2025: $90.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $323.37 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Dexcom, INC. | $183.95 | 2021-2023 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $141.63 | 2023 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $75.96 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.77 | 2019-2022 | |
| Allergan, INC. | $53.07 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $43.51 | 2021 | |
| Inspire Medical Systems, INC. | $38.57 | 2024-2025 | Inspire |
| Sanofi Pasteur INC. | $35.56 | 2019-2024 | |
| Cranial Technologies, INC | $34.92 | 2022-2024 | Doc Band |
| Supernus Pharmaceuticals, INC. | $31.50 | 2021-2025 | Qelbree |
| Pfizer INC. | $28.29 | 2022-2024 | |
| Lilly USA, LLC | $27.27 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $25.33 | 2019-2021 | |
| Boston Scientific Corporation | $23.15 | 2025 | General - Pain Management |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.40 | 2025 | |
| Abbott Laboratories | $19.95 | 2021 | |
| Exact Sciences Corporation | $14.94 | 2024 | |
| Astellas Pharma US INC | $14.87 | 2019 | |
| Kaleo, INC. | $13.74 | 2022 | |
| Seqirus USA INC | $12.75 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.